Status:
COMPLETED
The Effects of Hemodilution Methods in Patients Undergoing Primary Debulking Gynaecological Surgery
Lead Sponsor:
Zhejiang Cancer Hospital
Conditions:
Ovarian Neoplasm Epithelial
Eligibility:
FEMALE
18-65 years
Phase:
NA
Brief Summary
Primary cytoreductive surgery for ovarian cancer is an ideal setting to evaluate endothelial function under ANH and AHH, as the procedure is associated with moderately high blood loss. As the techniqu...
Detailed Description
Using a computer-generated random number table, patients were randomized to three groups: Control Group(n=30), ANH Group(n=30) and AHH Group(n=30). Patients underwent standard preoperative preparation...
Eligibility Criteria
Inclusion
- Clinical diagnosis of advanced primary epithelial ovarian
- No comorbidities nor functional limitations (ASA Grade II due to high tumor load)
- Serum hemoglobin (Hb) before surgery ≥ 11g/dl
- Hematocrit (Hct) ≥ 35%
- Quantity of platelets ≥ 100 × 109 /L
Exclusion
- Age \<18 or \>65 years
- Body mass index \<20 and \>30 kg/m2
- Duration of surgery \<180 min
- Severe cardiovascular disease, liver and kidney disease
- Thromboembolism history
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 31 2023
Estimated Enrollment :
144 Patients enrolled
Trial Details
Trial ID
NCT06103214
Start Date
January 1 2017
End Date
January 31 2023
Last Update
October 26 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.